title: Editorial Comment from Dr Miyata and Dr Sakai to Sulfoquinovosylacylpropanediol is a novel potent radiosensitizer in prostate cancer.
authors.affiliation: Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan. int.doc.miya@m3.dion.ne.jp.
authors.forename: Yasuyoshi
authors.initials: Y
authors.lastname: Miyata
authors.affiliation: Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
authors.forename: Hideki
authors.initials: H
authors.lastname: Sakai
mesh_terms: D000818:Animals; D001808:Blood Vessels / Q000528:radiation effects*; D006017:Glycolipids / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D009389:Neovascularization, Pathologic / Q000532:radiotherapy*; D011471:Prostatic Neoplasms / Q000098:blood supply* / Q000532:radiotherapy*; D011838:Radiation-Sensitizing Agents / Q000008:administration & dosage*
chemical_list: D006017:Glycolipids; D011838:Radiation-Sensitizing Agents; C000605760:sulfoquinovosylacylpropanediol